New Strategies in the Diagnosis and Treatment of Follicular Lymphoma: 2022 ASH Update – Enduring Webcast

Description

Program Description

---

Follicular lymphoma (FL) is the most common indolent lymphoma characterized by a relapsing and remitting course. In addition to significant biologic heterogeneity, the clinical trajectory for patients is variable, with some being observed for many years and others having aggressive diseases requiring multiple treatment courses. Unfortunately, FL remains incurable and continues to cause early mortality. Improved understanding of FL’s genetic and immune biology has led to several FDA-approved therapies in the relapsed and refractory setting, including PI3K inhibitors; immunomodulatory agents; the EZH2 inhibitor, tazemetostat; and anti-CD19 chimeric antigen receptor (CAR) T-cell therapies, axicabtagene ciloleucel, and tisagenlecleucel.

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals caring for FL

Commercial Supporter

---

This activity is supported by an educational grant from Genentech, a member of the Roche Group